What is Brinter?
Founded in 2020 and headquartered in Turku, Finland, Brinter® bioprinting company operates as the bioprinting division of 3DTech Oy. The company specializes in providing comprehensive 3D bioprinting solutions and services tailored for the pharmaceutical, biotechnological, and cosmetic sectors, as well as for universities and research facilities. Brinter's bioprinters are custom-built to meet the specific application requirements of each client, positioning the company as a key player in the rapidly evolving field of biofabrication.
How much funding has Brinter raised?
Brinter has raised a total of $1.4M across 1 funding round:
Angel/Seed
$1.4M
Angel/Seed (2021): $1.4M, investors not publicly disclosed
What's next for Brinter?
The recent major strategic investment signals Brinter's progression into a more mature phase of its growth trajectory, likely focusing on scaling operations, expanding its technological capabilities, and deepening its market penetration. This enterprise-level backing suggests a strategic alignment with investors who foresee substantial future value in advanced bioprinting technologies, particularly within the life sciences and advanced materials sectors. Brinter is poised to leverage this financing to accelerate product development and solidify its competitive advantage.
See full Brinter company page
